Chart: IoM's Comparative Effectiveness Research Priorities
You may also be interested in...
While there are many fears that comparative effectiveness research will be used to pick winners and losers when products are pitted against one another, United BioSource Corp.'s Bryan Luce does not see head-to-head trials becoming the primary focus of CER activity in the U.S., at least on the federal level
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials